Today Macrogen the leading Korean biotech company announced it’s working on a blockchain for genomic data. In June the company started working with Bigster, a local big data company.
In the past, the biotech company was the first to sequence a Korean genome fully. Macrogen highlighted the benefits of genomic analysis. It can help to predict or diagnose illnesses, and enable personalized treatment or even preventative care.
Personal DNA tests have become popular. This year it’s
estimated that 17 million people will buy personal tests. That’s more than four times the 2016 figure. On the other hand, pharmaceutical companies are keen to use the data for research into drugs and therapies.
Article continues …
Want the full story? Pro subscribers get complete articles, exclusive industry analysis, and early access to legislative updates that keep you ahead of the competition. Join the professionals who are choosing deeper insights over surface level news.
